Literature DB >> 31278635

Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria.

Masatoshi Sakurai1, Jun Ho Jang2, Wen-Chien Chou3, Jin Seok Kim4, Amanda Wilson5, Jun-Ichi Nishimura6, Tzeon-Jye Chiou7, Yuzuru Kanakura6, Jong Wook Lee8, Shinichiro Okamoto9.   

Abstract

A difference in clinical manifestations of paroxysmal nocturnal hemoglobinuria (PNH) among different races has been suggested. The aim of this study was to clarify whether the clinical characteristics of patients with PNH in the International PNH Registry differ by ethnic background. Patients, who were eculizumab naïve at baseline and had ≥ 1% PNH clone size, were eligible for this analysis. Totally, 1793 patients were enrolled and divided into two cohorts, Asian (N = 246) and non-Asian (N = 1547). The Asian cohort was further divided into Asians in Asia cohort (N = 202) and Asians in non-Asia cohort (N = 44), based on geographical region. The Asian cohort had significantly higher PNH clone size in granulocytes, higher lactate dehydrogenase levels, and lower hemoglobin levels. However, the frequencies of symptoms including abdominal pain, backache, easy bleeding, fatigue and headache at baseline were significantly lower in the Asian cohort. The proportion of patients with a history of thromboembolism (TE) was significantly lower in the Asian than in the non-Asian cohort (3.6% vs. 8.9%, P < 0.01); however, there was no difference between Asians in Asia and Asians in non-Asia (3.3% vs. 4.9%, P = 0.61). These findings suggested that genetic factors may play a stronger role in developing TE than lifestyle factors in PNH patients.

Entities:  

Keywords:  Asian; International PNH Registry; Paroxysmal nocturnal hemoglobinuria; Thromboembolism

Mesh:

Substances:

Year:  2019        PMID: 31278635     DOI: 10.1007/s12185-019-02699-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  24 in total

Review 1.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

2.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Neal S Young; Jörg Schubert; Robert A Brodsky; Gerard Socié; Petra Muus; Alexander Röth; Jeffrey Szer; Modupe O Elebute; Ryotaro Nakamura; Paul Browne; Antonio M Risitano; Anita Hill; Hubert Schrezenmeier; Chieh-Lin Fu; Jaroslaw Maciejewski; Scott A Rollins; Christopher F Mojcik; Russell P Rother; Lucio Luzzatto
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

3.  Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.

Authors:  Hubert Schrezenmeier; Petra Muus; Gérard Socié; Jeffrey Szer; Alvaro Urbano-Ispizua; Jaroslaw P Maciejewski; Robert A Brodsky; Monica Bessler; Yuzuru Kanakura; Wendell Rosse; Gus Khursigara; Camille Bedrosian; Peter Hillmen
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

4.  Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

Authors:  Richard J Kelly; Anita Hill; Louise M Arnold; Gemma L Brooksbank; Stephen J Richards; Matthew Cullen; Lindsay D Mitchell; Dena R Cohen; Walter M Gregory; Peter Hillmen
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

Review 5.  Thrombosis in paroxysmal nocturnal hemoglobinuria.

Authors:  Anita Hill; Richard J Kelly; Peter Hillmen
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

6.  Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.

Authors:  Jun-Ichi Nishimura; Yuzuru Kanakura; Russell E Ware; Tsutomu Shichishima; Hideki Nakakuma; Haruhiko Ninomiya; Carlos M Decastro; Sharon Hall; Akihisa Kanamaru; Keith M Sullivan; Hideaki Mizoguchi; Mitsuhiro Omine; Taroh Kinoshita; Wendell F Rosse
Journal:  Medicine (Baltimore)       Date:  2004-05       Impact factor: 1.889

7.  Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories.

Authors:  Régis Peffault de Latour; Jean Yves Mary; Célia Salanoubat; Louis Terriou; Gabriel Etienne; Mohamad Mohty; Sophie Roth; Sophie de Guibert; Sebastien Maury; Jean Yves Cahn; Gerard Socié
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

8.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Claire Hall; Judith C W Marsh; Modupe Elebute; Michael P Bombara; Beth E Petro; Matthew J Cullen; Stephen J Richards; Scott A Rollins; Christopher F Mojcik; Russell P Rother
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

9.  Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry.

Authors:  Jong Wook Lee; Jun Ho Jang; Jin Seok Kim; Sung-Soo Yoon; Je-Hwan Lee; Yeo-Kyeoung Kim; Deog-Yeon Jo; Jooseop Chung; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-05-01       Impact factor: 2.490

10.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113

View more
  2 in total

Review 1.  Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH).

Authors:  Kimmo Weisshaar; Hannah Ewald; Jörg Halter; Sabine Gerull; Sandra Schönfeld; Yuliya Senft; Maria Martinez; Anne Leuppi-Taegtmeyer; Nina Khanna; Birgit Maier; Antonio Risitano; Regis Peffault de Latour; Andre Tichelli; Jakob Passweg; Beatrice Drexler
Journal:  Orphanet J Rare Dis       Date:  2020-09-17       Impact factor: 4.123

2.  The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies.

Authors:  Coralina Bernuy-Guevara; Hassib Chehade; Yannick D Muller; Julien Vionnet; François Cachat; Gabriella Guzzo; Carlos Ochoa-Sangrador; F Javier Álvarez; Daniel Teta; Débora Martín-García; Marcel Adler; Félix J de Paz; Frank Lizaraso-Soto; Manuel Pascual; Francisco Herrera-Gómez
Journal:  Biomedicines       Date:  2020-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.